

Special Issue

New Insights into Esophageal Cancer Chemotherapy

Message from the Guest Editor

Recent advancements in esophageal cancer chemotherapy have provided valuable insights into more effective treatment strategies. Researchers have uncovered novel drug combinations that target specific molecular pathways involved in esophageal cancer progression. These approaches aim to enhance the efficacy of chemotherapy while minimizing adverse side effects. Additionally, personalized treatment plans based on a patient's genetic profile are becoming increasingly common, allowing for tailored therapies that improve overall outcomes. These innovative insights offer hope for more successful and less invasive management of esophageal cancer, potentially leading to improved patient survival rates and a better quality of life during treatment.

Guest Editor

Dr. Kenneth Meredith

Department of Surgical Oncology, Sarasota Memorial Hospital,
Sarasota, FL, USA

Deadline for manuscript submissions

20 August 2025



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/188720

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)